A novel B-cell receptor – nuclear repressor ZEB2 axis that defines the clinical outcome in Chronic Lymphocytic Leukaemia

Dr Sergey Krysov, Barts Cancer Institute & Centre for Haemato-Oncology, Queen Mary Hospital, London and John Goldman Fellow 2016

Sergey Krysov

The growing understanding of the protein markers on the surface of cancer cells helps to improve the success rate of blood cancer treatments.

According to the Office for National Statistics, Chronic Lymphocytic Leukaemia (CLL) is the most common malignant blood disease. Sadly, despite recent advances in drug development, CLL remains incurable and can transform into a highly aggressive form of cancer.

There are newly-approved drugs designed to block the function of the cancer cells. They do this by targeting the signalling functions of these proteins that reside on the surface of the cancer cell. And while they have entered the clinic, and are revolutionising treatment, they are sadly prohibitively expensive in most cases.

Dr Krysov’s research aims to unravel the control of the surface proteins and signalling inside CLL cells. If we better understand how these proteins and signalling functions work, we may be able to provide new targets for future drugs. Not only this, but we may be able to create treatments to work in tandem with the drugs already available, and optimise their use.

This research aims to investigate the effects of the factors that can directly influence the presence of the surface proteins and the subsequent effects in malignant cells.

Initiatives such as the John Goldman Fellowship pave the way for many more exciting projects and grant applications that will translate into more effective treatments for patients and eventually into a cure

Dr Sergey Krysov